(via NewsDirect)
Oldham said: “We continue to be grateful to the volunteers participating in this Phase 1 extension study.
“The favourable safety profile of AD-214 continues to be demonstrated at the anticipated Phase 2 clinical study doses.
“This study also supports our partnering program for AD-214 and we are pleased to have materially progressed several partnering and project financing discussions over the past month to help progress AD-214 into Phase 2 studies.”
Contact Details
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source